阿戈美拉汀与SSRIs治疗抑郁障碍疗效的Meta分析  

Meta analysis of the efficacy of agomelatine and SSRIs in the treatment of depressive disorders

作　　者：翁赛峥[1] 林晖 连宁 邹锦山 彭玲武 丛伟东[1] 陈华云[1] WENG Saizheng;LIN Hui;LIAN Ning;ZOU Jinshan;PENG Lingwu;CONG Weidong;CHEN Huayun(Affiliated Neuropsychiatric Hospital of Fujian Medical University,Fujian Province,Fuzhou 350008,China;不详)

机构地区：[1]福建医科大学附属神经精神病医院,福州市350008 [2]福建省罗源县精神病防治院,350605 [3]福建省福清市融康医院,350300 [4]福建省莆田市慈康医院,351100 [5]福建省宁德市福安精神病人疗养院,355000

出　　处：《临床合理用药杂志》2022年第16期23-26,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的比较阿戈美拉汀与选择性五羟色胺(5-HT)再摄取抑制剂(SSRIs)治疗抑郁障碍的疗效,为临床治疗提供循证医学参考。方法通过Medline、Pub Med、Wiley online library数据库检索英文文献,采用汉密尔顿抑郁量表(HAMD)及汉密尔顿焦虑量表(HAMA)评分减分作为抑郁症状及焦虑症状的改善指标,采用Rev Man 5.2统计软件进行Meta分析,比较阿戈美拉汀与SSRIs的疗效。结果最终纳入符合标准的文献6篇。阿戈美拉汀与SSRIs治疗抑郁症状[SMD=0.06(95%CI:-0.03,0.14)]与焦虑症状的改善效果[MD=0.12(95%CI:-0.82,1.06)]均无显著差异(P>0.05)。结论阿戈美拉汀与SSRIs治疗抑郁障碍的疗效相当。Objective To compare the efficacy of agomelatine and selective serotonin reuptake inhibitors(SSRIs)in the treatment of depression,and to provide evidence-based medicine reference for clinical treatment.Methods English literature was retrieved through Medline,Pub Med and Wiley online library databases,the Hamilton depression scale(HAMD)and Hamilton anxiety scale(HAMA)score reduction were used as improvement indicators to compare the efficacy of agomelatine and SSRI in the treatment of depressive symptoms and anxiety symptoms,Rev man 5.2 statistical software was used for Meta analysis.Results Six articles that met the criteria were finally included.There was no significant difference(P>0.05)in the improvement effect of agomelatine and SSRIs on depressive symptoms[SMD=0.06(95%CI:-0.03,0.14)]and anxiety symptoms[MD=0.12(95%CI:-0.82,1.06)].Conclusion The efficacy of agomelatine and SSRIs in the treatment of depression is comparable.

关 键 词：阿戈美拉汀 选择性五羟色胺再摄取抑制剂 META分析 抑郁 焦虑 

分 类 号：R749.4[医药卫生—神经病学与精神病学]